In this study, we have identified and validated a large series of patients affected by DTC, and created a three-domain scoring system able to identify the risk of persistence-relapse of disease after initial treatment (e.g., thyroidectomy and RAI). This three-domain system includes potential prognostic factors such as demographic (age and gender) and RAI-related (pre-RAI Tg […]
ABSTRACT Objective: The treatment of patients with differentiated thyroid cancer (DTC) was modified in thelast decade towards a more individualized approach according to the risk of recurrence (RR). Wecompared the outcomes of patients with low and intermediate RR (LRR and IRR) who received ordid not receive radioiodine remnant ablation (RRA) after assessing the dynamic risk. […]
Abstract Objectives: To determine the percentage of patients with papillary thyroid carcinoma (PTC) who accepted active surveillance as an alternative to surgery in our clinical practice and to describe the clinical characteristics and outcomes of patients with Bethesda category V and VI thyroid nodules who chose active surveillance. Subjects and methods: We included 136 PTC patients from […]
Abstract Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with […]
Summary Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid […]
